Anti- Bcl-1/Cyclin D1 (5D4) Mouse IgG MoAb - Biotin

Catalogue Number: 11012-IBL

Manufacturer:IBL - (Immuno-Biologicals Laboratories Co Ltd)
Physical state:Lyophilized product from 1% BSA in PBS containing 0.05%NaN3
Type:Monoclonal Primary Antibody - Unconjugated
Shipping Condition:Blue Ice
Storage Condition:2-8°C
Unit(s): 100 ug
Host name:
Clone: 5D4
Isotype: IgG2a
Immunogen: recombinant Human PRAD1/cyclin D1 (E. coli)

Description

Description: Bcl-1/Cyclin D1 belongs to the G1 cyclins and plays a key role in cell cycle regulation during the G1/S transition by cooperating with cyclin-dependent kinases (CDKs). Its overexpression may lead to growth advantage for tumor cells by way of cell cycle progression, and actually it has been reported in various human cancers, e.g., esophageal, breast, and bladder carcinomas. Among hematolymphoid malignancies, cyclin D1 overexpression resulting from translocational activation has also been recognized in a subset of B-chronic lymphocytic leukemia (B-CLL), multiple myeloma, splenic marginal zone lymphoma, hairy cell leukemia, and mantle cell lymphoma. Reference: 1. Banno S. et al. Monoclonal antibody against PRAD1/cyclin D1 stains nuclei of tumor cells with translocation or amplification at BCL-1 locus. Jpn. J. Cancer Res. 85, 918-926, 1994. 2. Nakamura S. et al. Immunohistochemical analysis of cyclin D1 protein in hematopoietic neoplasms with special reference to mantle cell lymphoma. Jpn. J. Cancer Res. 85: 1270-1231, 1994. 3. Kurada H. et al. The positive nuclear staining observed with monoclonal antibody against PRAD1/Cyclin D1 correlates with mRNA expression in mantle cell lymphoma. Jpn. J. Cancer Res. 86: 890-898, 1995. 4. Yatabe Y. et al. Clinicopathologic study of PRAD1/cyclin D1 overexpressing lymphoma with special reference mantle cell lymphoma, a distinct molecular pathologic entity. Amer. J. Surg. Pathol. 20: 1110-1122, 1996. 5. Yasogawa Y. et al. The 5D4 antibody (anti-cyclin D1/D2) related antigen: cyotoplasmic staining is correlated to the progression of gastric cancer. Pathology International. 48 (9), 717-722, 1998

Additional Text

Specificity

Cross-react with cyclin D2